BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sengul Samanci N, Ayer M, Ergen A, Ozturk S. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report. Transfus Apher Sci 2015;52:314-6. [PMID: 25634788 DOI: 10.1016/j.transci.2015.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
2 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
3 Matsumura D, Tanaka A, Nakamura T, Sato E, Node K. Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report. Clin Nephrol Case Stud 2016;4:24-8. [PMID: 29043138 DOI: 10.5414/CNCS108889] [Cited by in F6Publishing: 2] [Reference Citation Analysis]